Howard H. Bailey

5.6k total citations
108 papers, 4.2k citations indexed

About

Howard H. Bailey is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Howard H. Bailey has authored 108 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 35 papers in Molecular Biology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Howard H. Bailey's work include Cancer Treatment and Pharmacology (19 papers), Sulfur Compounds in Biology (9 papers) and Lymphoma Diagnosis and Treatment (8 papers). Howard H. Bailey is often cited by papers focused on Cancer Treatment and Pharmacology (19 papers), Sulfur Compounds in Biology (9 papers) and Lymphoma Diagnosis and Treatment (8 papers). Howard H. Bailey collaborates with scholars based in United States, Spain and Malaysia. Howard H. Bailey's co-authors include Ríona Mulcahy, Jerry J. Gipp, Hasan Mukhtar, George Wilding, Jeremy J. Johnson, Dona Alberti, Marcia Pomplun, Rick Chappell, Nihal Ahmad and Cameron O. Scarlett and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Howard H. Bailey

103 papers receiving 4.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Howard H. Bailey 1.9k 865 553 528 451 108 4.2k
Gillian Smith 2.1k 1.1× 1.5k 1.7× 489 0.9× 215 0.4× 447 1.0× 127 7.1k
Shangha Pan 3.0k 1.6× 843 1.0× 583 1.1× 382 0.7× 341 0.8× 121 5.3k
Marie H. Hanigan 1.8k 1.0× 687 0.8× 952 1.7× 1.0k 2.0× 233 0.5× 63 4.0k
Jaydutt V. Vadgama 2.4k 1.3× 1.6k 1.8× 485 0.9× 206 0.4× 355 0.8× 130 4.5k
Imad Shureiqi 1.7k 0.9× 1.0k 1.2× 302 0.5× 422 0.8× 383 0.8× 80 3.6k
Changyuan Wang 2.7k 1.4× 1.5k 1.8× 494 0.9× 207 0.4× 347 0.8× 255 6.1k
Joseph Wu 3.0k 1.6× 793 0.9× 563 1.0× 123 0.2× 424 0.9× 236 6.9k
Neil R. Kitteringham 3.1k 1.7× 937 1.1× 358 0.6× 298 0.6× 172 0.4× 92 7.3k
Leszek Wojnowski 2.5k 1.3× 1.8k 2.1× 421 0.8× 189 0.4× 308 0.7× 93 6.1k
Margie L. Clapper 1.9k 1.0× 714 0.8× 267 0.5× 156 0.3× 302 0.7× 95 3.2k

Countries citing papers authored by Howard H. Bailey

Since Specialization
Citations

This map shows the geographic impact of Howard H. Bailey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard H. Bailey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard H. Bailey more than expected).

Fields of papers citing papers by Howard H. Bailey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard H. Bailey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard H. Bailey. The network helps show where Howard H. Bailey may publish in the future.

Co-authorship network of co-authors of Howard H. Bailey

This figure shows the co-authorship network connecting the top 25 collaborators of Howard H. Bailey. A scholar is included among the top collaborators of Howard H. Bailey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard H. Bailey. Howard H. Bailey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bailey, Howard H., Cameron O. Scarlett, Thomas C. Havighurst, et al.. (2024). Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery. Cancer Prevention Research. 18(1). 31–39. 1 indexed citations
3.
Kim, KyungMann, et al.. (2023). Non-melanoma skin cancer event rates in a formalized clinical trial setting: considerations for clinical trial design. European Journal of Cancer Prevention. 33(1). 69–72. 1 indexed citations
4.
Jarrard, David F., Wei Huang, KyungMann Kim, et al.. (2020). A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance. The Prostate. 81(1). 41–49. 24 indexed citations
5.
Favarato, Graziella, Helen Peters, Rebecca Sconza, et al.. (2019). Stillbirth in women living with HIV delivering in the UK and Ireland: 2007-2015. UCL Discovery (University College London).
6.
Kolesar, Jill, Heather Green, Douglas Laux, et al.. (2019). A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. Cancer Prevention Research. 12(12). 903–912. 5 indexed citations
7.
Bailey, Howard H., Linus Chuang, Nefertiti C. duPont, et al.. (2016). American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. Journal of Clinical Oncology. 34(15). 1803–1812. 60 indexed citations
8.
Fabian, Carol J., Bruce F. Kimler, Carola M. Zalles, et al.. (2015). Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer. Cancer Prevention Research. 8(12). 1146–1155. 14 indexed citations
9.
Rocque, Gabrielle B., Jens C. Eickhoff, Howard H. Bailey, et al.. (2013). Inpatient Hospitalization of Oncology Patients: Are We Missing an Opportunity for End-of-Life Care?. Journal of Oncology Practice. 9(1). 51–54. 85 indexed citations
10.
Kim, KyungMann, Eneida A. Mendonça, Gary S. Wood, et al.. (2012). A Phase III Skin Cancer Chemoprevention Study of DFMO: Long-term Follow-up of Skin Cancer Events and Toxicity. Cancer Prevention Research. 5(12). 1368–1374. 34 indexed citations
11.
Elmets, Craig A., Jaye L. Viner, Alice P. Pentland, et al.. (2010). Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial. JNCI Journal of the National Cancer Institute. 102(24). 1835–1844. 167 indexed citations
12.
Bailey, Howard H., KyungMann Kim, Ajit Kumar Verma, et al.. (2010). A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer. Cancer Prevention Research. 3(1). 35–47. 71 indexed citations
13.
Afaq, Farrukh, Sami Sarfaraz, Deeba N. Syed, et al.. (2006). Cannabinoid receptors as a target for therapy of ovarian cancer. Cancer Research. 66. 1084–1084. 2 indexed citations
14.
Kahl, Brad S., Walter Longo, Jens C. Eickhoff, et al.. (2006). Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Annals of Oncology. 17(9). 1418–1423. 82 indexed citations
15.
Yuan, Zheng, Rick Chappell, & Howard H. Bailey. (2006). The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach. Biometrics. 63(1). 173–179. 103 indexed citations
16.
Hartenbach, Ellen M., Elizabeth A. Grosen, Howard H. Bailey, et al.. (2002). Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2. Genetic Testing. 6(2). 75–78. 8 indexed citations
17.
Mulkerin, Daniel, et al.. (2002). Phase II Trial of Perillyl Alcohol in Patients with Metastatic Colorectal Cancer. International Journal of Gastrointestinal Cancer. 32(2-3). 125–128. 47 indexed citations
18.
Thomas, James P., Kendra D. Tutsch, James F. Cleary, et al.. (2002). Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemotherapy and Pharmacology. 50(6). 465–472. 100 indexed citations
19.
Bailey, Howard H.. (1998). l-S,R-buthionine sulfoximine: historical development and clinical issues. Chemico-Biological Interactions. 111-112. 239–254. 155 indexed citations
20.
Bailey, Howard H., et al.. (1991). Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.. PubMed. 51(4). 1105–8. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gillian Smith Breakdown of academic impact, for papers by Shangha Pan Breakdown of academic impact, for papers by Marie H. Hanigan Breakdown of academic impact, for papers by Jaydutt V. Vadgama Breakdown of academic impact, for papers by Imad Shureiqi Breakdown of academic impact, for papers by Changyuan Wang Breakdown of academic impact, for papers by Joseph Wu Breakdown of academic impact, for papers by Neil R. Kitteringham Breakdown of academic impact, for papers by Leszek Wojnowski Breakdown of academic impact, for papers by Margie L. Clapper
Rankless by CCL
2026